-
1 Comment
Hangzhou Tigermed Consulting Co.,Ltd is currently in a long term uptrend where the price is trading 11.4% above its 200 day moving average.
From a valuation standpoint, the stock is 292.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 37.8.
Hangzhou Tigermed Consulting Co.,Ltd's total revenue rose by 15.5% to $892M since the same quarter in the previous year.
Its net income has increased by 37.7% to $432M since the same quarter in the previous year.
Finally, its free cash flow grew by 152.9% to $471M since the same quarter in the previous year.
Based on the above factors, Hangzhou Tigermed Consulting Co.,Ltd gets an overall score of 4/5.
Sector | Healthcare |
---|---|
ISIN | CNE100001KV8 |
Industry | Diagnostics & Research |
CurrencyCode | CNY |
Exchange | SHE |
Target Price | 138.56 |
---|---|
Market Cap | 88B |
Dividend Yield | 0.5% |
Beta | 0.82 |
PE Ratio | 45.48 |
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300347.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024